- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00057577
Prevention of Recurrence in Depression With Drugs and CT (CPT3)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
It is commonly believed that the combination of ADM and psychotherapy is more effective in treating depression than either treatment alone. Data indicate that CT enhances the initial effects of ADM, but little research has been conducted to determine whether prior exposure to CT prevents the onset of new depressive episodes. This study will determine the effectiveness of adding CT to ADM for the treatment of depression.
Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue cognitive therapy; all recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush Medical Center - Treatment Research Unit
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Depression Research Unit, University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Vanderbilt Adult Outpatient Psychiatry
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Recurrent or chronic major depressive disorder
Exclusion Criteria:
- Current diagnosis of psychotic affective disorder
- History of nonaffective psychotic disorder
- Substance dependence last three months requiring detox
- Schizotypal, antisocial, or borderline personality disorder
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Cognitive therapy plus medications
Participants will receive antidepressant medication plus cognitive therapy
|
CT sessions occur weekly during acute treatment and monthly during continuation.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery.
At recovery, patients receiving combined treatment discontinue CT.
Autres noms:
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Autres noms:
|
Expérimental: Medications alone
Participants will receive maintenance of antidepressant medication alone
|
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants in Remission According to the Longitudinal Interval Follow-up Evaluation (LIFE) and the Hamilton Rating Scale for Depression (HRSD)
Délai: Through month 18 of treatment
|
Remission defined as four consecutive weeks of LIFE Problem Symptom Rating (PSR) values of 2 or less and HRSD scores of 8 or less for four consecutive weeks (with partial remission defined as LIFE PSR values of 3 or less and HRSD scores of 12 or less after month 12 only)
|
Through month 18 of treatment
|
Number of Participants in Recovery According to the LIFE and HRSD
Délai: Through 36 months of treatment
|
Six consecutive months following remission without relapse (two weeks of elevated LIFE PSR scores of 4 or more and HRSD scores of 14 and above)
|
Through 36 months of treatment
|
Number of Participants in Recurrence According to the LIFE and HRSD
Délai: Measured up to Month 36 from recovery
|
Recurrence defined as two consecutive weeks of elevated LIFE PSR scores of 5 or above and HRSD scores of 16 or above (three weeks during period of medication withdrawal)
|
Measured up to Month 36 from recovery
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Serious Adverse Events
Délai: Throughout study, up to 54 months
|
Number Serious Adverse Events (SAEs) as reported to the Institutional Review Boards and Data Safety Monitoring Board throughout the duration of the study
|
Throughout study, up to 54 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Steven D. Hollon, PhD, Vanderbilt University
- Chercheur principal: Jan A. Fawcett, MD, Rush Medical Center
Publications et liens utiles
Publications générales
- Khazanov GK, Xu C, Hollon SD, DeRubeis RJ, Thase ME. Adding cognitive therapy to antidepressant medications decreases suicidal ideation. J Affect Disord. 2021 Feb 15;281:183-191. doi: 10.1016/j.jad.2020.12.032. Epub 2020 Dec 8.
- Khazanov GK, Xu C, Dunn BD, Cohen ZD, DeRubeis RJ, Hollon SD. Distress and anhedonia as predictors of depression treatment outcome: A secondary analysis of a randomized clinical trial. Behav Res Ther. 2020 Feb;125:103507. doi: 10.1016/j.brat.2019.103507. Epub 2019 Oct 31.
- DeRubeis RJ, Zajecka J, Shelton RC, Amsterdam JD, Fawcett J, Xu C, Young PR, Gallop R, Hollon SD. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 Mar 1;77(3):237-245. doi: 10.1001/jamapsychiatry.2019.3900. Erratum In: JAMA Psychiatry. 2020 Jan 29;:
- Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1157-64. doi: 10.1001/jamapsychiatry.2014.1054.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- R01MH060713 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cognitive Therapy
-
VA Office of Research and DevelopmentComplétéTroubles de stress, post-traumatiqueÉtats-Unis
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)Actif, ne recrute pasAccident vasculaire cérébral | Aphasie | Aphasie Non FluentÉtats-Unis
-
University of WashingtonNational Institute on Drug Abuse (NIDA)ComplétéTroubles liés à l'utilisation de substances | Troubles de stress post-traumatique | Sexe à risqueÉtats-Unis
-
Columbia UniversityRésilié
-
NeuroTronik Inc.InconnueInsuffisance cardiaque | Insuffisance cardiaque aiguëParaguay
-
NeuroTronik Inc.InconnueInsuffisance cardiaque aiguëPanama
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...ComplétéEn bonne santéSuisse
-
University of Alabama at BirminghamComplétéAccident vasculaire cérébral | Parésie du membre supérieur | AVC (Accident Cérébrovasculaire)États-Unis
-
Abbott Medical DevicesComplétéFibrillation auriculaire paroxystiqueAustralie, Allemagne, France, Italie, Le Portugal, Royaume-Uni
-
University of Roma La SapienzaComplétéÉchec de l'implant dentaire | Mucosite buccaleItalie